Current standards and novel concepts in thrombotic thrombocytopenic purpura
Johannes Bloehdorn, Mark S. Cragg, Martin Bommer · 2026
Read Current standards and novel concepts in thrombotic thrombocytopenic purpura by Johannes Bloehdorn, Mark S. Cragg, Martin Bommer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13621958.txt.
Description
Johannes Bloehdorn, Mark Cragg, and Martin Bommer review care for a rare, fast-killing blood disorder. Their 2026 paper covers thrombotic thrombocytopenic purpura, where missing enzyme activity lets giant protein strands clog tiny vessels. Most cases are immune attacks on the enzyme; a few are born with the lack. Enzyme testing anchors diagnosis, with scores guiding care while results pend.
Plasma exchange and immune suppression remain the core cure for the immune form. A newer nanobody drug blocks clotting during attacks but does not stop the immune attack itself. Lab-made enzyme has reshaped care for the born form. Relapse still stalks survivors, so long follow-up is a must. The review maps fresh tests that may predict relapse.
Catalog record
| CREATOR | Johannes Bloehdorn, Mark S. Cragg, Martin Bommer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 87 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |